Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Gene Delivery Technologies Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.
The global gene delivery technologies market is currently witnessing an impressive growth trajectory, with expectations of reaching a value of $6.96 billion by 2028 at a compound annual growth rate (CAGR) of 14.1%. A comprehensive market research publication, shedding light on the intricate dynamics of the sector, has now been added to our extensive repository of industry analyses.
Advancements in cell and gene therapies are turbocharging the market, with a burgeoning number of clinical trials and FDA approvals heralding a new era of medical treatments. The escalating prevalence of genetic disorders is further propelling the gene delivery technologies landscape, offering robust opportunities for key market players.
Technological innovation continues to be a defining trend, with leading companies pioneering next-generation delivery platforms. These platforms are revolutionizing the precision and efficiency of cell and gene therapies, unlocking tremendous potential for personalized medicine and disease treatment.
The extensive market report encapsulates pivotal developments, including strategic company acquisitions that aim to amplify capabilities in viral vector technologies, thereby fortifying the framework for gene therapy advancements across diverse medical conditions.
Market Overview:
The market landscape is marked by its diversification across biological, chemical, and physical gene delivery methods, each playing an integral role in the continuum of gene therapy, cell therapy, vaccines, and research applications.
Geographically, North America maintains the largest market share, underscored by a robust infrastructure and substantial investments in R&D. However, Asia-Pacific is rapidly materializing as the fastest-growing region, indicative of the significant opportunities emerging in these economies.
Key Report Insights:
- Forecasts predict a compelling growth trajectory for the gene delivery technologies market, with a CAGR of 14.1% leading to a potential market size of $6.96 billion by 2028.
- Cell and gene therapies are major growth drivers due to advancements in genetic editing technologies and a growing number of clinical trials.
- The rise in genetic disorders globally places gene delivery technologies at the forefront of medical innovation.
- Technological advancements and strategic market acquisitions are reshaping the competitive landscape.
- Comprehensive coverage of the market spans revenue projections, technological trends, and key player strategies.
A selection of companies mentioned in this report includes
- Thermo Fisher Scientific Inc.
- QIAGEN NV
- Horizon Discovery Group Co
- OriGene Technologies Inc.
- Oxford Biomedica Solutions LLC
- SignaGen Laboratories LLC
- Vectalys SAS
- Takara Bio Inc.
- Bio-Rad Laboratories Inc.
- System Biosciences LLC
- Promega Corporation
- Hoffmann-La Roche AG
- Catalent Inc.
- Avantor
- Pfizer Inc.
- Becton Dickinson and Company
- Novartis AG
- Intellia Therapeutics Inc.
- Editas Medicine Inc.
- CRISPR Therapeutics AG
- Spark Therapeutics Inc.
- Bluebird Bio Inc.
- Sarepta Therapeutics Inc.
- Regenexxbio Inc.
- Beam Therapeutics Inc.
- Verve Therapeutics Inc.
- Arrowhead Pharmaceuticals Inc.
- Alnylam Pharmaceuticals Inc.
- Moderna Inc.
- BioNTech SE
- Translate Bio Inc.
- CureVac N.V.
- Lonza Group AG
For more information about this report visit https://www.researchandmarkets.com/r/r9f62b
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
